{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-034574","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2025-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.973364+00:00","generated_at":"2026-05-25T07:11:42.449175+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut","bullets":["GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.","Cash & equivalents $131.3M as of Dec 31, 2024; expects cash runway into Q4 2026 after ~30% workforce reduction.","ASPEN-06 Phase 2: evorpacept combo cORR 48.9% vs 24.5% control in HER2+ gastric cancer; median DOR 15.7 vs 9.1 months.","Leadership changes: appointed CBO, CMO, CFO; founder Jaume Pons steps down as President, becomes Senior Scientific Advisor.","Upcoming catalysts: ASPEN-03/04 HNSCC topline data Q2 2025; regulatory guidance on gastric cancer path Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-034574","json":"https://secwatch.observer/filing/0000950170-25-034574.json","markdown":"https://secwatch.observer/filing/0000950170-25-034574.md","text":"https://secwatch.observer/filing/0000950170-25-034574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/0000950170-25-034574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/alxo-20250306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T07:11:42.449175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}